Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.14), $0.01 better than the analyst estimate of ($0.15).

Third Quarter 2015 and Recent Highlights

• Completed enrollment in Phase II, randomized, double-blind, placebo-controlled multicenter clinical trial of NurOwn® in ALS.
• Successful completion of Data and Safety Monitoring Board review of Phase II clinical trial of NurOwn® in amyotrophic lateral sclerosis (ALS).
• Appointment of Chaim Lebovits at Chief Executive Officer, building on strategic and operational experience, and history of leadership at BrainStorm.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.